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Abstract
Immune cells are involved in virtually every aspect of the wound repair process, from
the initial stages where they participate in haemostasis and work to prevent infection
to later stages where they drive scar formation. Immunotherapy is being developed
offers some advantageous immunomodulation factors that are known in the field of
alternative  medicine,  such  as  mushroom  beta-glucan,  anti-microbial  peptides  and
triterpenoid; these factors represent a novel therapeutic approach for anti-inflammation
to promote the wound healing.
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1. Inflammation
When an organism is injured by a wound injury or infected by a pathogen, inflammation is a
crucial response. Inflammation is a complex interaction with molecular mediators; it includes
the function of immune cells in a microenvironment through a response that occurs at all levels
of  biological  organisation  [1].  Following previous  studies,  this  paper  illustrates  that  the
inflammation response involves cooperation between cells and a wide range of mediators,
such as cytokines, chemokines and non-enzyme factors involved in the classical immune
response. The macrophage is one of the critical inflammatory immune cells involved in the
uptake and degradation of infectious agents and senescent cells and also plays critical roles in
tissue growth, tissue remodelling and inflammation by producing oxidants, proteinases and
anti-microbial peptides [2–4]. Activated inflammatory cells are sources of reactive oxygen
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species (ROS) and reactive nitrogen species (RNS) that can initiate changes in cell functions,
including  cell  signalling  pathways,  transcription  factor  activation,  mediator  release  and
apoptosis. However, whether the ROS and RNS that are produced and released by neutrophils
or macrophages are sufficient to diffuse through the extra-cellular matrix, enter epithelial cells
and cross the cytoplasm is not clear [5–7]. Even the physiological roles of ROS and RNS in the
cellular response are not clear [8–11]. The results obtained from experiments performed on
the  livers  of  tilapia  showed  that  extra-cellular  hydrogen  peroxide  (H2O2)  attracted  cell
migration. These results suggested that ROS is a crucial factor in initiating the migration of
macrophages that trigger cascades of phagocytic activity.
In the microenvironment of inflammation, the platelet-derived growth factor (PDGF), the
tumour necrosis factors (TNF)-α and TNF-β, the hepatocyte growth factor, transforming
growth factor (TGF)-β2, the epidermal growth factor (EGF) and the fibroblast growth factor
all play an important role in physiological immune response. The interleukins (IL)-1, IL-6, IL-8,
IL-10, and the interferon gamma (INF-γ) also detain key functions in the natural inflammatory
response [12–16]. These factors hold a primordial function in fibroblast activation and regu-
lation, also concerning reactive fibrosis that follows their continuing activation. Although these
growth factors are also related to fibroblast migration and activation, particular research was
recently focused on the PDGF family of growth factors and their relative receptors [17, 18].
Research has documented that PDGF exerts autocrine, mitogenic effects on keratinocytes to
support epidermal proliferation and stabilisation of the epidermal junction during wound
closure. In addition, it stimulates vessel maturation by recruiting and differentiating pericytes
to the immature-endothelial channel [19–22]. According to these references, we investigate
whether the produced ROS/RNS is related to the released factors and (if so) what type of
relationship exists among ROS/RNS and these factors.
2. Reactive oxygen species production and physical response
The production and scavenging of ROS may be initiated by adverse environmental factors.
Research has shown that intra-cellular levels of ROS may rapidly rise and ROS may be
generated by the activation of various oxidases and peroxidases in response to certain
environmental changes [23]. ROS forms through energy transfer or through electron transfer
reactions. ROS formation causes the formation of singlet oxygen, which results in sequential
reduction to superoxide, H2O2 and hydroxyl radicals [24]. Mitochondria are a crucial source
of ROS production in most cells. This ROS production contributes to mitochondrial stress and
plays a critical role in redox signalling from the organelles [25]. Mitochondria have a 4-layer
structure composed of the outer mitochondrial membrane, intermembrane space, inner
mitochondrial membrane and matrix [26]. NADPH oxidase is an enzymatic source in the
mitochondrial structure that generates ROS and plays a fundamental role in maintaining
normal cell functions. Recent research has focussed on the influence of this enzyme to cellular
oxidative stress that may contribute to various pathophysiological conditions and diseases [27,
28]. A crucial function of NADPH oxidase is modulating multiple redox-sensitive intra-cellular
signalling pathways; NADPH modulates these pathways by generating ROS molecules,
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inhibiting protein tyrosine phosphatases and activating certain redox-sensitive transcription
factors. Moreover, the ROS consist of numerous molecular species, including H2O2, oxide ions
(O2) and hydroxide (OH−) [29]. Molecular oxygen is a biradical, containing two unpaired
electrons in the outer structure; because these two electrons have the same spin, oxygen can
only react with one electron; therefore it is not very reactive when these two electrons have the
same spin. Oxygen’s unpaired electrons can become excited and can change the spin of one
electron. This transforms oxygen into a powerful oxidant because the two electrons with
opposing spins can rapidly react with other pairs of electrons [30]. Electrons can be contributed
from NADH and FADH2 enzymes and can pass through the electron transport chain, gener-
ating superoxide (O2−) at complexes I and III. This generated superoxide can be reduced to
H2O2 by superoxide dismutase and can be completely reduced into water by glutathione
peroxidase, as presented in Figure 1.
Figure 1. ROS are produced from the electron transport pathway to form superoxide (O2−) at complex I and complex III
released into the matrix and reduced O2 to form H2O at complex IV. Following, the generated O2− is transferred to the
form of H2O2 by superoxide dismutase (SOD) and completely reduced to water (H2O) by glutathione peroxidase
(GPX).
Research has shown that ROS consist of numerous molecular species, including H2O2, oxide
ions (O2−) and OH−29. These molecular species act as signalling molecules in the migration of
profibrogenic cells [31] and peripheral blood monocytes [23, 32]. One of the crucial physio-
logical functions of ROS is the modulation of ion channels. Research has illustrated that ROS
may act through Ca2+ as an intra-cellular second messenger involved in regulating diverse
functions, such as fertilisation, electrical signalling, contraction, secretion, memory, gene
transcription and cell death [33, 34]. Furthermore, studies have reported that H2O2 may affect
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cell energy stores [35], induce DNA strand breaks [36], enhance cell adhesion [37], increase
endothelial tissue permeability [38] and stimulate the release of cytokines.
In the research presented in Figure 2, the concentration of ROS seems to be considered the
concentration of a crucial signalling molecule. Low concentrations of generated ROS are
believed to be critical for metabolic adaptation in the organelle. Moderate concentrations of
ROS can be produced and released by stress; pathogen-infected and bacterial endotoxin
lipopolysaccharide (LPS) are involved in the inflammatory response. The high concentration
of ROS in the induced apoptosis/autophagy process can cause cell death [39] and initiate self-
healing [40].
Figure 2. Concentration of generated ROS may involve in the different physiological response. At the low concentra-
tion, the ROS regulate in the redox signalling, and at the moderate concentration of induced ROS which participated in
the inflammation process. At the high level of ROS concentration increased and was to be involved in the cellular
apoptosis.
3. Tissue resident macrophages
Macrophages, which are present in almost all body tissue and display distinct location-specific
phenotypes and gene expression profiles, display remarkable functional diversity in innate
immune responses, tissue development and tissue homeostasis [41]. In different organs, the
resident macrophages are given various appellations: microglia cells have fundamental
importance in assessing the pathogenetic significance of perivascular inflammatory phenom-
ena within the brain [42]; Kupffer cells are resident and recruited macrophages that play major
roles in the homeostatic function of the liver and in its response to tissue damage [43]; alveolar
macrophages are key determinants pulmonary immune responses and in the lung inflamma-
tion caused by asthma [44]. Previously, it was hypothesised that tissue macrophages were
recruited from circulating blood monocytes. Recent studies have demonstrated that tissue
macrophages such as microglia, Kupffer cells and Langerhans cells are established prenatally
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and arise independently of the hematopoietic transcription factor Myb [45]. Myb is required
for developing hematopoietic stem cells (HSCs) and all CD11bhigh monocytes and macrophages
but is not required for yolk sac (YS) macrophages and for developing YS-derived F4/80bright
macrophages. Such macrophages can persist independently of HSCs in several types of tissue
in adult mice [46]. Kupffer cells as well as other resident macrophages (e.g., microglia) originate
from the YS in a colony-stimulating factor-1/receptor (CSF-1R)-dependent and Myb-inde-
pendent manner. Researchers have suggested that these macrophages are maintained by local
proliferation, which results in extensive mitosis after stress or an exchanged tissue microen-
vironment [43, 47].
Macrophages are the most crucial and abundant immune cells. They can be categorised into
two primary types according to function and differentiation: classically activated macrophages
(M1 macrophages) and alternatively activated macrophages (M2 macrophages) [48]. Macro-
phages are relevant to innate resistance and to the relationship between inflammation and
autoimmune disease. In mouse models, macrophages present CD11b, F4/80 and CSF-1R, with
F4/80 being the surface proteins for M1 and M2 macrophages [49, 50]. When pathogens enter
the organism from the intestinal portal vein, circulating monocytes (surrounding the patho-
gens and present in the peripheral blood) respond to chemokines (e.g., CCL2) and are exposed
to antigens. While interacting with pattern recognition receptors (PRRs), antigens may exert
either M1 or M2 polarising activities, depending on the Th1 (IFN-γ) and Th2 (IL-4 and IL-13)
cytokines and immune factors [51, 52].
4. Inflammation and macrophages
Inflammation is an important adaptive physiological response of the organism. Inflammation
response embodies a complicated interaction among molecular mediators and cells. It globally
affects the leukocytes, also the lymphocytes in their micro-environmental function and
organisation [48]. Throughout their response, numerous factors are involved in the classical
immune response. Macrophages detain a critical role in the uptake and degradation of
infectious agents and senescent cells; they also play crucial roles in tissue growth, tissue
remodelling and inflammation by producing oxidants, proteinases and anti-microbial
peptide [40].
Resident macrophages sense exogenous or endogenous danger signals (e.g., bacterial products
or necrotic cell debris) through PRRs. In response to Toll-like receptor (TLR) ligands and
interferon-gamma (IFN-γ) or IL-4/IL-13, macrophages undergo M1 (classical) or M2 (alterna-
tive) activation. The activation of M1 and M2 macrophages mirrors TH1-TH2 polarisation; M1
and M2 activation span the extremes of a continuum. M1 macrophages, which display a
morphology that depends on their tissue location, develop in response to stimulation with
IFN-γ and microbial products such as LPS. M1 macrophages can secrete substantial amounts
of pro-inflammatory cytokines, such as IL-1β, IL-15, IL-18, TNF-α and IL-12 [53]. M2 macro-
phages adapt to similarities and differences between IL-4, TLR ligands with IL-10 and
glucocorticoids [54].
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The phenotypes of M1 and M2 macrophages exhibit observable differences. The M1 phenotype
is characterised by the expression of high levels of pro-inflammatory cytokines, high produc-
tion of reactive nitrogen and oxygen intermediates, promotion of Th1 response and anti-
microbial and tumour-inhibiting activity [43]. The M2 macrophage uses immune inhibitory
effects to secrete large amounts of IL-10, TGF-β, and C-C motif chemokine ligands 17 (CCL17)
and CCL22. Moreover, the M2 macrophage attracts non-cytotoxic Treg and Type 2 T-helper cells
(TH2 cells) to aggregate in tumour tissue, inhibit T-cell differentiation and function, lower
cytotoxic T-cell function, induce T-cell apoptosis, secrete CCL18 and attract naive T cells [55].
Macrophage M1 M2
Transcription factor




Nuclear factor NF-κB [43]
Signal transducer and activator
of transcription





of cytokine signalling SOCS-2
(SOCS) SOCS-3
(controversial) [58]
Phenotype iNOS [69, 70] YM-1 [71]
IL-6 [72] Arg-1 [73, 74]
TNF-α [75] Fizz-1 [76]
IL-10 [77]
Table 1. Regulators in the M1 and M2 macrophage.
Macrophage polarisation is highly related to expressions of various TLRs on macrophages [56,
57]. The evidence indicates that TLR signalling (e.g., TLR4), which is activated by LPS and
other microbial ligands, drives macrophages to prefer the M1 phenotype. In this reaction,
MyD88 and TRIF activate a cascade of kinases, including IRAK4, TRAF6 and IKKβ; this results
in the activation of nuclear factor kappa B (NF-κB), which drives the macrophage forward to
the M1 phenotype. By contrast, IL-4 and IL-13 drive the macrophage’s phenotype forward to
M2. Activation of STAT6 through the IL-4 receptor alpha (IL-4Rα) and IL-10 induce activation
of STAT3 through receptor IL-10R, which activates JAK1 and JAK3 (38), causing STAT6
activation [58, 59]. IL-10, TGF-β, IL-4 and IL-13 enhance inflammation and cellular immune
response with NO, which is generated through IFN-γ-induced iNOS and is reduced in
macrophages by Arg1 interactions with mast cells, basophils, eosinophils, NKT cells, IgE and
selected subclasses of IgG. This promotes allergies and hypersensitivity [60] (Table 1).
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5. Inflammation and disease
Accumulating evidence indicates that chronic low-grade inflammation contributes to the
systemic metabolic dysfunction that is associated with inflammation disorders [78]. Cytokines
and pathogen-associated molecular patterns have been shown to co-stimulate cell surface
receptors, including TLRs, to initiate intra-cellular signalling that activates NF-κB. NF-κB
activation was thought to induce the target gene’s expression to promote cellular proliferation
and to activate the immune response. However, research has revealed that NF-κB activation
can occur in most cell types; recent reports have demonstrated that high level activation of NF-
κB signalling pathways in the liver, adipose tissue and central nervous system (CNS) is
involved in the development of inflammation-associated metabolic diseases [79]. The mutants
of the brain-specific serpin, neuroserpin, also form ordered polymers that accumulate within
the ER of neurons; these mutations cause an autosomal-dominant type of dementia known as
familial encephalopathy with neuroserpin inclusion bodies, which is believed to be an
inflammation disorder [80, 81].
Research has shown that, in specific tissue lesions, extra-cellular lipid droplets are forming a
core region surrounded by smooth muscle cells and collagen-rich matrix. Lymphocytes as the
T cells, monocyte, macrophages and mast cells are infiltrating in the lesion particularly in
regions where the atheroma grows. These immune cells also generate important signals in the
defence cascade by producing the inflammatory cytokines, largely involved in the athero-
sclerotic process [82]. A case report indicated that Alzheimer’s disease (AD) inflammation
appears to arise from within the CNS. Little or no involvement of lymphocytes or monocytes
in AD was observed beyond their normal brain surveillance. This observation has placed AD
outside the realm of conventional neuroimmunologic studies that largely focus on humoral
aspects of such CNS inflammatory disorders as multiple sclerosis [83]. Judging from published
reports, we believe that metabolic disorders and even neuronal diseases are highly related to
abnormal inflammation.
6. Macrophage and T-cell differentiation
In pathogen infection, dendritic cells (DCs) and macrophages primarily act as phagocytotic
antigen-presenting cells (APCs) that degrade infected pathogens into fragments, and then
move those fragments to the nearby lymphoid organs. The pathogen fragments combine with
cell surface histocompatibility complex (major histocompatibility complex) to activate and
differentiate T cells. Figure 3 displays the cooperation of the antigen-presenting cells, co-
stimulatory molecules and cytokines.
The metabolic organs, such as the liver, pancreas and adipose tissue, are composed of paren-
chymal and stromal cells, which include macrophages to maintain metabolic homeostasis.
Bacterial infection innately activates macrophages, causing the secretion of proinflammatory
cytokines, such as TNF-α, IL-6 and IL-1β. This promotes peripheral insulin resistance and
reduces nutrient storage during the metabolic reaction. Furthermore, some additional
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physiological mechanism can lead to the activation of macrophages. For these latest, the
regulatory T cells (Treg), the Fcγ receptors, the apoptotic cells and the prostaglandins are
increasing the number of macrophages involved in the regulation of inflammation and anti-
tumour defences [84]. These inflammatory mediators are involved in activating anti-microbial
defence mechanisms, including oxidative processes that contribute to killing pathogens and
the secreted IL-12 and IL-23. These direct the differentiation and expansion of anti-microbial
TH1 and TH17 cells that help to drive inflammatory responses [85]. Recent research shows that
intestinal antigen-presenting cells can be divided into CD11c+CD11b−, CD11c+CD11b+ and
CD11cdullCD11b+ categories. Particularly, the CD11cdullCD11b+ cells are CD103−F4/80+macro-
phages, with efficient role in inducing the Foxp3+ regulatory T (Treg) cells [86]. Tumour cells
affect the surrounding cellular environment by promoting tumour growth and metastasis by
establishing a tumour microenvironment that is conducive to tumour development [87–90].
In the tumour microenvironment, tumour cells secrete inflammatory cytokines, such as TGF-
β and IL-10. These cytokines stimulate differentiation of regulatory T and Treg cells [91, 92] as
well as differentiation of tumour-associated macrophages (TAMs) into M2 macrophages. This
causes the host immune system to locate and attack cancer cells, which generates subsequent
tumour cell evasion of this immune surveillance and attack, which enhances tumour growth
and metastasis [87, 93–98]. Various cytokines, chemokines and growth factors in the tumour
microenvironment are the primary elements that affect the host’s anti-tumour ability and
evasion of tumour cells [89, 99]. Tumour microenvironments are complicated cellular micro-
cosms [89, 97], and numerous immune cells are located throughout tumour microenviron-
ments. Macrophages are the most crucial and abundant immune cells in the tumour
microenvironment. The two most critical types of macrophages, based on function and
differentiation, are M1 and M2 macrophages. M1 macrophages are characterised by tumour
Figure 3. The cooperation of the antigen-presenting cells, costimulatory molecules, and cytokines. Bacterial infection
innately activates macrophages, causing the secretion of pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-1β.
This promotes peripheral insulin resistance and reduces nutrient storage during the metabolic reaction. Furthermore,
several additional mechanisms can also contribute to the activation of macrophages for immune-regulatory activity.
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resistance, whereas M2 macrophages are characterised by tumour promotion [98, 100]. In
mouse models, macrophages present CD11b, F4/80, CSF-1R and F4/80 as the surface proteins
for M1 and M2 macrophages [93, 101]. Recent studies have noted large quantities of TAMs in
tumour tissue. TAMs are the most abundant and critical immune cells in the tumour micro-
environment [102–104] and are the main factors that enable the tumour microenvironment to
exert immune inhibitory effects [101, 102]. In the tumour microenvironment, tumour cells and
the surrounding stoma cells secrete cytokines and growth factors that stimulate TAMs and
activate the various expression, function, receptor regulation and secretion types of chemo-
kines [103, 105], including anti-tumour M1 macrophages and pro-tumour M2 macrophages
[98, 106–108]. In the tumour microenvironment, the proportions of M1 and M2 macrophages
are unequal. Tumour microenvironments contain large amounts of transmitters, such as M-
CSF, IL-6, IL-10, TGF-β and COX-2, that induce transformation of TAMs into M2 macrophages
that secrete immune inhibitory chemokines and have poor antigen-presenting and cytotoxic
abilities, which generates tumour growth and metastasis [49, 98, 102–104, 109–114]. M2
macrophages and TAMs have protumour and immune inhibitory effects, secrete large
amounts of IL-10, TGF-β, CCL17 and CCL22, attract non-cytotoxic Treg and TH2 cells to
aggregate in tumour tissue, inhibit T-cell differentiation and function, lower cytotoxic T-cell
function, induce T-cell apoptosis, secrete CCL18 and attract naïve T cells [49, 98, 115]. NADPH
oxidase is a major enzymatic source of cellular ROS. NADPH plays a fundamental role in
maintaining normal cell functions. Recent research has focussed on this enzyme’s role in
cellular oxidative stress, which may eventually contribute to various pathophysiological
conditions and diseases [27, 28]. Studies have found that NADPH oxidase modulates multiple
redox-sensitive intra-cellular signalling pathways by generating ROS molecules. This modu-
lation includes inhibition of protein tyrosine phosphatases and activation of certain redox-
sensitive transcription factors [116, 117]. ROS consist of numerous molecular species,
including H2O2, oxide ions (O2−) and OH−29, that act as signalling molecules involved in the
migration of hepatic profibrogenic cells [118] and the functioning of peripheral blood mono-
cytes [119]. ROS and RNS, generated endogenously or in response to environmental stress,
have long been implicated in tissue injury for a variety of disease states [120, 121]. Stimulation
of the mitochondrial apoptotic pathway through ROS and mitochondrial DNA damage
promotes outer membrane permeabilisation, which triggers caspase-dependent or caspase-
independent cytosolic signalling events [122]. Activated inflammatory cells serve as sources
of ROS and RNS that can initiate the alteration of the cell function, gathering specific cellular
signalling, transcription factor activation, physiological factors release, the apoptosis process
and compensatory cell proliferation. However, it remains unclear whether the ROS or the RNS
production and release through neutrophils or macrophages enhance sufficient diffusion into
the intra-cellular cytoplasm as to affect the cellular response [123, 124].
7. Wound healing
Immune cells are involved in virtually every aspect of the wound repair process, from the
initial stages, where they participate in haemostasis and work to prevent infection, to later
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stages where they drive scar formation [125, 126]. T lymphocytes exercise crucial in vivo effects
on various parameters of healing [127–129]. Neutrophils help control infection during wound
healing, but they also release harmful enzymes that damage healthy tissue surrounding the
wound site [130–132]. Recent researchers have noted that several specific proteins produced
by wound macrophages at the site of injury are involved: (1) in the recruitment and activation
of additional macrophages infiltrating in the wound; (2) in the production of growth factors
that promote cellular proliferation and tissue recovery synthesis; (3) in stimulating proteases
and extra-cellular matrix growth and (4) in the process of tissue remodelling [133]. β-catenin-
dependent Wnt pathways, which are classified according to their ability to promote stabilisa-
tion of β-catenin in the cytoplasm, act as cellular signals through cytoplasmic stabilisation and
accumulation of β-catenin in the nucleus to activate gene transcription [134]. This could
enhance wound healing by lymphocytes [135, 136]. Nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase modulates multiple redox-sensitive intra-cellular signalling
pathways by generating ROS molecules. This includes inhibiting protein tyrosine phospha-
tases and activating certain redox-sensitive transcription factors [116, 137, 138]. This shows
that ROS regulate the expression of key chemical mediators that further modulate the
inflammatory response in animal models; it has also been reported that these redox-sensitive
processes may include cytokine action, angiogenesis, cell motility and extra-cellular matrix
formation [139–141]; this can enable reliable estimates of wound-healing capacity, which is
altered by various conditions, such as inflammation. Furthermore, research on one of the ROS
has indicated that H2O2 plays a critical role in wound repair, inflammation and anti-inflam-
mation mechanisms [142, 143]. Our published research also showed that the production of
ROS (i.e., H2O2 after an injury has occurred) may cause healing to generate inflammation
through the apoptosis of the cell. Over-inhibition of NADPH oxidase activity may reduce the
normal progress of apoptosis under the wound and might delay healing [29].
Inflammation enhances vascular permeability, active migration of blood cells and the passage
of plasma constituents into the injured tissue [144]. Blood leukocytes actively participate in the
defence and inflammation responses, being activated since the earliest phases of atheroscle-
rosis process. Inflammation and atherosclerosis shelter intricate mechanisms relied to leuko-
cytes recruitment [145]. Neuro-inflammation mediators are described to be closely related to
brain cells functioning (such as microglia and astrocytes), to the complement system activation
and to cytokines, and chemokines production [146]. Regarding cancer development [147], pro-
inflammatory cytokines, including IL-1α, IL-1β, IL-6, IL-8, IL-18, chemokines, matrix metal-
lopeptidase-9 and vascular endothelial growth factor, are primarily regulated by the
transcription NF-κB, which is active in most tumours and is induced by carcinogens [148].
Cutaneous wound repair is a tightly regulated and dynamic process involving blood clotting,
inflammation, formation of new tissue and tissue remodelling [149]. Thrombin is the protease
involved in blood coagulation. Its deregulation can cause haemostatic abnormalities, which
range from subtle subclinical problems to serious life-threatening coagulopathies (i.e., during
septicaemia) [150]. Inflammation and coagulation are both parts of the natural mechanism that
protects the organism against infection. The endothelial cells and the platelets are capable to
react in the acute, also in the chronic inflammatory environment. They release pro-inflamma-
tory mediators that produce adhesion of molecules, proteases and clotting factors associated
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to leukocytes recruitment [151]. The elements of the PAR family serve as sensors that detect
blood-clotting serine proteinases in the inflamed target cells. Activation of PAR-1 by thrombin
and of PAR-2 by other factors on the membrane of endothelial cells generates rapid expression
and exposure of adhesive proteins that mediate an acute inflammatory reaction and of the
tissue factor that initiates the blood coagulation cascade [152] as presented as Figure 4.
Figure 4. Wound healing was initiated after the injury of the cell, tissue even the organ. In the early stage of the heal-
ing, the damaged tissue producing a lot of ROS leading to neighbour cells into the apoptosis, following the apoptotic
cells collapsed and released caspases were able to induce the tissue repair. However, the imbalance inflammatory may
induce over-production of blood glucose that is leading to decrease the EGF receptor expression further to impair the
wound healing.
8. Immunomodulation in anti-inflammation therapy
Nakanishi et al. found that celecoxib can alter the immune inhibitory effects of the tumour
microenvironment by promoting transformation of TAMs into M1 macrophages, inhibiting
tumour growth [153]. In 1968, Ikekawa et al. found that the fruiting body extracts from Lentinus
edodes, Trametes versicolor, Ganoderma tsugae, Flammulina velutiper and Tricholoma matsutake
demonstrated substantial anti-tumour activities towards transplanted tumour cells of Sarcoma
180 [154, 155]. Autrodia comphorata-derived beta-glucan inhibited tumour growth for Sarcoma
37, Sarcoma 180, Erlich ascites sarcoma and Yoshida sarcoma as well as inhibited LLC1
transplanted tumour growth [156]. Daily intake of A. comphorata-derived beta-glucan for 18
consecutive days was demonstrated to slow tumour growth and reduce the rate of metastasis
[157]. Cytotoxic T-cell activity and tumour occurrence rates were observed, and the results
illustrated that daily oral intake of Grifola frondosua-derived beta-glucan or Lentinan can
enhance cytotoxic T-cell activity and reduce tumour occurrence rates [158]. The addition of a
conditioned medium along with tumour cells into the progenitor cells of DCs was found to
further inhibit maturation of DCs and lower the antigen-presenting capability of the DCs [159].
Tumour cells were found to secrete M-CSF, inhibiting dendritic and T-cell differentiation and
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anti-tumour ability [87, 159–161]. In the inflammation environment, the amounts of M1 and
M2 macrophages are not equal [162]. The tumour environment contains vast quantities of
transmitters such as M-CSF, IL-6, IL-10, TGF-β and COX-2 that induce tumour megakaryocytes
to differentiate into M2 macrophages, which, in addition to having inferior antigen-presenting
and cytotoxic abilities, also secrete factors that inhibit immune cells, resulting in enhanced
immune inhibitory effects in the tumour environment [49, 98, 102–104, 109–114]. M2 macro-
phages in tumour bearing mice enhance tumour growth and immune inhibitory effects. They
also secrete cytokines, such as IL-10 and TGF-β, in high quantities, which attract non-cytotox-
ic Treg cells and TH2 cells to congregate in tumour tissue; those cells inhibit the differentiation
and normal function of T cells, including their cytotoxic ability, and further promote T-cell
apoptosis [49, 98, 115, 163, 164]. The polarisation of TH1 and TH2 is built on cytokine patterns;
polarisation begins when the antigen-presenting cells interact with naive T cells; they polarise
into Type 1 (TH1) and TH2 cells in response to the type of antigen encountered [165]. TH1 and
TH2 cells secrete different cytokines; TH1 cells rely on IL-2, IFN-γ and TNF, which are involved
in cell-mediated immunity against pathogens, but TH2 cells depend mostly on IL-4 and IL-5,
which stimulate the production of IgE antibodies and eosinophil responses, resulting in
allergic diseases [166, 167]. Although an imbalanced TH1/TH2 immune response is linked to
certain hypersensitivity disorders such as allergies, asthma and hay fever [168], studies have
suggested that using a biological response modifier to restore the balance between TH1 and
TH2 immune response can be a potential treatment option for IgE-dependent hypersensitivi-
ty [169]. Ganoderma lucidum is a medicinal mushroom that has been widely used as a folk
medicine in Asian countries such as China and Japan for hundreds of years for its immuno-
modulating and anti-tumour effects. Numerous biologically available substances with
immunity enhancement effects, particularly polysaccharides, have been isolated from the
extract of G. lucidum [170].
Anti-microbial peptides are effective components of innate immunity that exist widely in
biological systems. One of the specific anti-microbial peptides, hepcidin, is a 25-amino acid
antibiotic peptide synthesised in the liver. Hepcidin is responsible for regulating iron balance
and recycling iron in humans and mice. Studies have reported 0–100 μg/ml concentrations of
hepcidin incubated with HT1080, Hep-G2 and HeLa for 24 h. The results have indicated higher
growth inhibition ratios after 70 μg/ml treatment with hepcidin in HT1080 cells; the treatment
has been very effective in inhibiting the growth of fibrosarcoma cells [171, 172]. Tachyplesin is
an anti-microbial peptide present in the leukocytes of the horseshoe crab (Tachypleus tridenta‐
tus); it inhibited the growth of TSU tumour cells on the CAM of chicken embryos as well as
the growth of B16 tumour cells in syngenic mice; moreover, it blocked the proliferation of both
tumour and endothelial cells in culture in a dose-dependent manner, whereas proliferation
was relatively unaffected in non-tumourigenic cell lines Cos-7 and NIH-3T3 [173]. D-K4R2L9
is a peptide comprised of Leu, Lys and Arg residues, totalling 15 amino acid residues that bind
to and lyse B16-F10 mouse melanoma cells in culture at concentrations that do not harm normal
3T3 fibroblasts or erythrocytes; this can be conducted to prevent intravenous-injected D122
lung carcinoma cells from forming lung tumours in mice [174, 175]. Bovine lactoferricin
(LfcinB), an anti-microbial peptide, is a 25-amino acid long highly basic peptide with a disulfide
bridge between two cysteines, thus giving it a cyclic twisted anti-parallel β-sheet solution
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structure. LfcinB has been tested on neuroblastoma growth in vivo; nude rats carrying SH-
SY-5Y xenografts were given injections of 1.0 or 2.0 mg LfcinB; these rats’ cancer was signifi-
cantly inhibited after LfcinB treatment, compared with untreated controls [176]. Anti-microbial
peptides can activate specific innate immune responses and immunomodulatory effects in the
host, even if the host is at risk or has been damaged. Furthermore, researchers have proposed
that anti-microbial peptides can modulate the host’s immune system through inflammatory
responses and can stimulate beneficial inflammation; anti-microbial peptides might be able to
inhibit tumour growth.
9. Conclusion
From the injury to the wound recovery, there are a series of physiological responses that occur
in relation to immune cells. Polarisation of the macrophage is an important response in wound
healing. A series of inflammatory factors are cited having notable function in the differentiation
from novel macrophage into the classical macrophage (M1). The cellular mechanism involved
in the regulation of classical macrophage (M1) and alternative macrophage (M2) was docu-
mented in the wound healing process. At the present time, the M1/M2 differentiation was
studied for selected immune responses. However, future studies may allow possible thera-
peutic targets considering this process in wound healing.
The immunotherapy that is being developed offers some advantageous immunomodulation
factors that are known in the field of alternative medicine, such as mushroom beta-glucan,
anti-microbial peptides and triterpenoid; these factors represent a novel therapeutic approach
for anti-inflammation. These factors may be a viable alternative approach to the problem of
drug resistance. Recent insights into wound healing and anti-inflammation are promising;
however, exploiting these insights is complex because it involves chemistry, biology, instru-
mentation science and formulation science. Discovering new methods that are more effective
in targets is difficult. Immunotherapy might be an alternative therapy that can be applied in
the early phases of clinical therapy. Similarly, immunomodulation might be applicable in the
early phases of immune disease.
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